Curium US LLC

Quick facts

Phase 3 pipeline

• Abiraterone with Prednisone or Enzalutamide · Oncology
  Abiraterone inhibits CYP17A1 to block androgen synthesis, while enzalutamide antagonizes the androgen receptor, together suppressing testosterone-driven prostate cancer growth; prednisone provides glucocorticoid support to mitigate mineralocorticoid excess from abiraterone.
• Copper Cu 64 PSMA I&T · Oncology
  Copper Cu 64 PSMA I&T is a radioactive diagnostic and therapeutic agent that binds to prostate-specific membrane antigen (PSMA) on cancer cells for imaging and treatment.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Curium US LLC portfolio CI brief
• Curium US LLC pipeline updates RSS